BCL7B抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P10296(BCL7B Antibody) at dilution 1/85. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10296(BCL7B Antibody) at dilution 1/85. (Original magnification: ×200)    

  
  

The BCL7B antibody targets the BCL7B protein, a member of the BCL7 family implicated in chromatin remodeling and transcriptional regulation. BCL7B is a subunit of the BAF (BRG1/BRM-associated factor) complex, part of the SWI/SNF chromatin-remodeling family, which plays a critical role in modulating gene expression by altering chromatin structure. Dysregulation of BCL7B and its associated complexes has been linked to cancers, particularly B-cell lymphomas, where chromosomal translocations involving BCL7B and oncogenes like MYC or BCL6 may drive tumorigenesis. Additionally, BCL7B is involved in neurodevelopmental processes, with studies suggesting its role in neuronal differentiation and synaptic plasticity.

Antibodies against BCL7B are primarily used in research to study its expression, localization, and interactions within cellular pathways. These tools are essential for techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to explore BCL7B's role in normal physiology and disease. However, variability in antibody specificity has been reported, necessitating careful validation to ensure reliable results. BCL7B antibodies have also contributed to understanding its tumor-suppressive or oncogenic functions, depending on cellular context, and its potential as a therapeutic target. The gene encoding BCL7B is located on chromosome 7q21.3. and its protein product typically migrates at ~25-30 kDa in SDS-PAGE. Ongoing research aims to clarify its precise mechanisms in chromatin dynamics and disease pathology.